SLC29A2 and Huntington disease: The inhibition of ENT-1/ENT-2 has also been shown to produce beneficial effects on the animal models of HD (Kao et al., 2017) and AD (Lee et al., 2018), stress echocardiography (Koeppen et al., 2009), mucosal inflammation (Aherne et al., 2018), and acute lung injury (Eckle et al., 2013).